Arrowhead Pharmaceuticals

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Arrowhead Pharmaceuticals, Inc. - ARWR

Retrieved on: 
Wednesday, February 23, 2022
GLOBE, Arrowhead, Arrowhead Pharmaceuticals, Hypoxia, RNA, NASDAQ, Pomerantz, Clear cell renal cell carcinoma, TKI, LLP, Chronic inflammatory demyelinating polyneuropathy, Myocarditis, News, RNA interference, Company, Cardiomyopathy, Patient, History, AES, Pharmaceutical industry

NEW YORK, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Arrowhead Pharmaceuticals, Inc. (Arrowhead or the Company) (NASDAQ: ARWR).

Key Points: 
  • NEW YORK, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Arrowhead Pharmaceuticals, Inc. (Arrowhead or the Company) (NASDAQ: ARWR).
  • Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext.
  • The investigation concerns whether Arrowhead and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.

Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Arrowhead Pharmaceuticals, Inc. (ARWR) Investigation

Retrieved on: 
Monday, February 21, 2022
Legal, Professional Services, Arrowhead, Arrowhead Pharmaceuticals, Hypoxia, RNA, Clear cell renal cell carcinoma, TKI, Company, NYSE, LLC, Chronic inflammatory demyelinating polyneuropathy, Myocarditis, News, RNA interference, Cardiomyopathy, Patient, History, AES, Private investigator, Pharmaceutical industry

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Arrowhead Pharmaceuticals, Inc. ("Arrowhead" or "the Company") (NYSE: ARWR).

Key Points: 
  • Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Arrowhead Pharmaceuticals, Inc. ("Arrowhead" or "the Company") (NYSE: ARWR).
  • Investors who purchased Arrowhead securities are encouraged to obtain additional information and assist the investigation by visiting the firms site: www.bgandg.com/arwr .
  • The investigation concerns whether Arrowhead and certain of its officers and/or directors have violated federal securities laws.
  • You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484.

Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Arrowhead Pharmaceuticals, Inc. (ARWR) Investigation

Retrieved on: 
Friday, February 18, 2022
Legal, Professional Services, History, NYSE, Patient, Arrowhead, Cardiomyopathy, Company, Hypoxia, RNA, RNA interference, Arrowhead Pharmaceuticals, TKI, Chronic inflammatory demyelinating polyneuropathy, Myocarditis, Clear cell renal cell carcinoma, News, LLC, AES, Private investigator, Pharmaceutical industry

Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Arrowhead Pharmaceuticals, Inc. ("Arrowhead" or "the Company") (NYSE: ARWR).

Key Points: 
  • Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Arrowhead Pharmaceuticals, Inc. ("Arrowhead" or "the Company") (NYSE: ARWR).
  • Investors who purchased Arrowhead securities are encouraged to obtain additional information and assist the investigation by visiting the firms site: www.bgandg.com/arwr .
  • The investigation concerns whether Arrowhead and certain of its officers and/or directors have violated federal securities laws.
  • You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484.

Arrowhead Pharmaceuticals Initiates Phase 1/2 Study of ARO-C3 for Treatment of Complement Mediated Diseases

Retrieved on: 
Friday, February 18, 2022
Cardiology, Biotechnology, Pharmaceutical, Oncology, Health, Infectious Diseases, Genetics, Clinical Trials, NASDAQ, Patient, Arrowhead, Company, Arrowhead Pharmaceuticals, Volunteering, Private Securities Litigation Reform Act, RNA, U.S. Securities and Exchange Commission, Security (finance), Gene silencing, Ariad Pharmaceuticals, Inc. v. Eli Lilly & Co., Adult, Safety, Annual report, Mission statement, Therapy, RNA interference, PNH, Twitter, Degenerative disease, Immunoglobulin A, Pharmacokinetics, IgA nephropathy, COVID-19, News, Trial of the century, MBA, Gene, Paroxysmal nocturnal hemoglobinuria, Pharmaceutical industry

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has dosed the first subjects in AROC3-1001, a Phase 1/2 clinical study of ARO-C3, the companys investigational RNA interference (RNAi) therapeutic designed to reduce production of complement component 3 (C3) as a potential therapy for various complement mediated diseases.

Key Points: 
  • Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has dosed the first subjects in AROC3-1001, a Phase 1/2 clinical study of ARO-C3, the companys investigational RNA interference (RNAi) therapeutic designed to reduce production of complement component 3 (C3) as a potential therapy for various complement mediated diseases.
  • James Hamilton, M.D., MBA, senior vice president of discovery and translational medicine at Arrowhead, said: We believe a C3 targeted drug has the potential to address multiple complement mediated and complement associated diseases, where significant unmet medical need exists.
  • These include IgA nephropathy, C3 glomerulopathy, paroxysmal nocturnal hemoglobinuria, and additional renal and hematologic diseases that we intend to evaluate in the future.
  • Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them.

Arrowhead Presents New Clinical Data on ARO-HIF2 at ASCO GU 2022

Retrieved on: 
Thursday, February 17, 2022
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, NASDAQ, History, RCC, Society, Patient, Arrowhead, Biomarker, Urine, Cardiomyopathy, Company, Arrowhead Pharmaceuticals, Neoplasm, RECIST, Private Securities Litigation Reform Act, Hypoxia, University of Texas Southwestern Medical Center, RNA, U.S. Securities and Exchange Commission, Gene silencing, KPS, Ariad Pharmaceuticals, Inc. v. Eli Lilly & Co., CA, Cohort, Response evaluation criteria in solid tumors, Security (finance), Safety, Performance status, Annual report, Mission statement, Therapy, RNA interference, TKI, Twitter, Chronic inflammatory demyelinating polyneuropathy, Plasma, HIF, Pharmacokinetics, Myocarditis, Serum, Clear cell renal cell carcinoma, Anemia, COVID-19, News, University, Investor, ASCO, Gene, AES, Pharmaceutical industry, Medical imaging

The data are being presented by James Brugarolas, M.D., Ph.D, Professor at University of Texas Southwestern Medical Center and investigator in the study, in a poster presentation at the 2022 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU), being held February 17-19, 2022, in San Francisco, CA and online.

Key Points: 
  • The data are being presented by James Brugarolas, M.D., Ph.D, Professor at University of Texas Southwestern Medical Center and investigator in the study, in a poster presentation at the 2022 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU), being held February 17-19, 2022, in San Francisco, CA and online.
  • AROHIF21001 ( NCT04169711 ) is a Phase 1b dose-finding clinical study in patients with advanced ccRCC to evaluate the safety of ARO-HIF2 and to determine the recommended Phase 2 dose.
  • Secondary objectives include the assessment of pharmacokinetics and preliminary efficacy, based on Response Evaluation Criteria in Solid Tumors (RECIST).
  • Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them.

Arrowhead Pharmaceuticals Announces Closing of Agreement with GlaxoSmithKline

Retrieved on: 
Monday, January 24, 2022
Biotechnology, Pharmaceutical, Genetics, Health, GlaxoSmithKline, News, Merrell Dow Pharmaceuticals Inc. v. Thompson, Hart–Scott–Rodino Antitrust Improvements Act, Private Securities Litigation Reform Act, Arrowhead Pharmaceuticals, COVID-19, Safety, NASDAQ, Arrowhead, Mission statement, U.S. Securities and Exchange Commission, GSK, Security (finance), Annual report, Pharmaceutical industry

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that the exclusive license agreement between Arrowhead and GlaxoSmithKline (LSE/NYSE: GSK) announced on November 22, 2021, has now closed.

Key Points: 
  • Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that the exclusive license agreement between Arrowhead and GlaxoSmithKline (LSE/NYSE: GSK) announced on November 22, 2021, has now closed.
  • Closing of the transaction was subject to customary closing conditions and expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended.
  • Any statements contained in this release except for historical information may be deemed to be forward-looking statements.
  • We assume no obligation to update or revise forward-looking statements to reflect new events or circumstances.

Arrowhead Pharmaceuticals to Webcast Fiscal 2022 First Quarter Results

Retrieved on: 
Friday, January 21, 2022
Infectious Diseases, FDA, Genetics, Clinical Trials, Cardiology, Biotechnology, General Health, Pharmaceutical, Health, Oncology, Webcast, News, Conference, RNA interference, Private Securities Litigation Reform Act, RNA, COVID-19, Safety, NASDAQ, Arrowhead, Mission statement, Gene, U.S. Securities and Exchange Commission, Gene silencing, Company, Therapy, Twitter, Security (finance), Arrowhead Pharmaceuticals, Annual report, Pharmaceutical industry

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on February 2, 2022, at 4:30 p.m.

Key Points: 
  • Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on February 2, 2022, at 4:30 p.m.
  • ET to discuss its financial results for the fiscal 2022 first quarter ended December 31, 2021.
  • The forward-looking statements in the webcast speak only as of the original date of the webcast.
  • We assume no obligation to update or revise forward-looking statements contained in the webcast to reflect new events or circumstances.

Arrowhead Pharmaceuticals Initiates Phase 3 PALISADE Study of ARO-APOC3 for Treatment of Familial Chylomicronemia Syndrome

Retrieved on: 
Wednesday, January 12, 2022
Biotechnology, Health, Genetics, Pharmaceutical, Clinical Trials, Patient, News, Ariad Pharmaceuticals, Inc. v. Eli Lilly & Co., Triglyceride, RNA interference, Private Securities Litigation Reform Act, RNA, Arrowhead Pharmaceuticals, COVID-19, FCS, Safety, Adult, C3, NASDAQ, Arrowhead, Mission statement, Gene, Pancreatitis, Hypertriglyceridemia, AHA, U.S. Securities and Exchange Commission, Genetics, Fasting, Program, Gene silencing, Company, Diagnosis, APOC3, Therapy, Risk, Twitter, Security (finance), Genetic testing, Trial of the century, Annual report, Pharmaceutical industry, Vaccine, PALISADE

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has dosed the first patients in the PALISADE study, a Phase 3 clinical study to evaluate the efficacy and safety of ARO-APOC3 in adults with familial chylomicronemia syndrome (FCS).

Key Points: 
  • Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has dosed the first patients in the PALISADE study, a Phase 3 clinical study to evaluate the efficacy and safety of ARO-APOC3 in adults with familial chylomicronemia syndrome (FCS).
  • ARO-APOC3 is currently being investigated in multiple clinical studies, including the Phase 3 PALISADE study in patients with FCS, the Phase 2b SHASTA-2 study in patients with severe hypertriglyceridemia (SHTG), and the Phase 2b MUIR study in patients with mixed dyslipidemia.
  • Javier San Martin, M.D., chief medical officer at Arrowhead, said: Initiating the Phase 3 PALISADE study is an important milestone for the ARO-APOC3 program, for patients with FCS, and for Arrowhead.
  • We look forward to investigating ARO-APOC3 in the larger Phase 3 PALISADE study to further assess its efficacy and safety.

Karyopharm Promotes Sohanya Cheng to Chief Commercial Officer

Retrieved on: 
Monday, January 10, 2022
SEC, Management, Bachelor of Science, Risk, Endometrial cancer, LinkedIn, Security (finance), Industry, Head, MBA, Multiple myeloma, Leadership, Marketing, United Kingdom, Patient, Commercial Operating System (COS), Adult, U.S. Securities and Exchange Commission, Ruxolitinib, B-cell lymphoma, University, Science, Arrowhead Pharmaceuticals, Microdeletion syndrome, MIT Sloan School of Management, Food, Patent, Research, Private Securities Litigation Reform Act, Therapy, Union, Company, Nasdaq, Corporate Affairs, KPTI, COVID-19, Twitter, MA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, SINE, Adoption, Pharmaceutical industry, Amgen

NEWTON, Mass., Jan. 10, 2022 /PRNewswire/ --Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that Sohanya Cheng has been promoted to Chief Commercial Officer.

Key Points: 
  • NEWTON, Mass., Jan. 10, 2022 /PRNewswire/ --Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that Sohanya Cheng has been promoted to Chief Commercial Officer.
  • Ms. Cheng joined Karyopharm in 2021 as Senior Vice President of Sales and Commercial Operations.
  • "Since joining Karyopharm, she has played a significant role in shaping our commercial strategy and strengthening capabilities, resulting in an increase in product revenue in 2021.
  • Sohanya's continued guidance and leadership will be invaluable and I look forward to more great things from her as our new chief commercial officer."

Arrowhead Initiates Project to Build New Manufacturing and Lab Facilities

Retrieved on: 
Monday, December 20, 2021
Health, Genetics, General Health, Pharmaceutical, Cardiology, Biotechnology, U.S. Securities and Exchange Commission, RNA, Company, Mission statement, Growth, Private Securities Litigation Reform Act, Industry, COVID-19, Annual report, Pleasure, NASDAQ, Foot, EUA, CEO, RNA interference, Research, Gene, Gene silencing, Safety, Therapy, Security (finance), Arrowhead Pharmaceuticals, Multimedia, Twitter, CA, GMP, News, Arrowhead, Pharmaceutical industry

Arrowhead intends to invest between $200 million and $250 million into the buildout of the facilities.

Key Points: 
  • Arrowhead intends to invest between $200 million and $250 million into the buildout of the facilities.
  • The Company expects that the new facilities will result in the creation of approximately 250 new jobs in the local area.
  • Arrowhead will continue to operate additional research and development facilities in Madison, WI, and San Diego, CA.
  • We have built strong local relationships and are pleased to continue our growth with the new Arrowhead campus that will include a new GMP manufacturing facility and associated lab and office facility.